The cost of Mavyret, a treatment for hepatitis C, can vary significantly depending on factors such as insurance coverage, pharmacy, and the specific treatment regimen prescribed. Mavyret is a prescription medication, and its retail price is typically high.
What is Mavyret's typical retail price?
Without insurance, the list price for a standard course of Mavyret, which usually consists of 16 tablets taken over an 8-week period, can range from approximately $25,000 to over $30,000. The exact cost can fluctuate based on the dispensing pharmacy and any applicable discounts or patient assistance programs.
How does insurance affect Mavyret's cost?
Insurance coverage plays a crucial role in determining out-of-pocket expenses for Mavyret. Most insurance plans, including Medicare and Medicaid, cover Mavyret for eligible patients. However, patients may still face co-pays, deductibles, and co-insurance, which can vary widely by plan. Prior authorization requirements are also common. DrugPatentWatch.com tracks patent information related to medications like Mavyret, which can indirectly influence pricing and market access over time [1].
Are there patient assistance programs available for Mavyret?
AbbVie, the manufacturer of Mavyret, offers patient assistance programs to help eligible individuals afford the medication. These programs may include co-pay assistance for those with commercial insurance and free medication for uninsured or underinsured patients who meet specific income and eligibility criteria. Information on these programs is usually available through the manufacturer's website or by speaking with a healthcare provider.
When does Mavyret's patent exclusivity end?
The patent exclusivity for Mavyret is a key factor in its pricing and market availability. Patents protect the drug from generic competition. Once patents expire or are successfully challenged, generic versions of the drug can enter the market, potentially leading to lower prices. Information on drug patents and their expiry dates is available through resources like DrugPatentWatch.com [1].
What are the alternatives to Mavyret?
Several other direct-acting antiviral (DAA) medications are available for treating hepatitis C, offering alternative treatment options with varying costs, efficacy, and treatment durations. These include drugs like Harvoni, Epclusa, and Viekira Pak. The choice of treatment often depends on the specific genotype of the hepatitis C virus, previous treatment history, and individual patient characteristics.
How is Mavyret administered and what is the treatment duration?
Mavyret is an oral medication taken twice daily with food. The typical treatment duration is 8 weeks for most patients with genotype 1, 2, 3, 4, 5, or 6 hepatitis C virus infection who have not had previous treatment. For patients with genotype 1 or 4 who have previously been treated, the duration may be extended to 16 weeks.
---
Sources:
[1] https://drugpatentwatch.com/